Altered pharmacokinetics of selected psychopharmaceuticals in patients with chronic kidney disease

Psychiatrick onemocnn a delirantn stavy len psychofarmaky jsou astou komorbiditou u pacient s pokozenm ledvin. Akoliv je zait pedstava, e vtina psychofarmak je lipofiln povahy a renln se neeliminuj, tak pro celou adu bn podvanch liv to neplat a jejich dvkovn je nutn u pacient s chronickm onemocnnm ledvin (CKD), nebo akutnm pokozenm ledvin (AKI) upravit. Pedkldan lnek se vnuje vlivu zhorench ledvinovch funkc a extrakorporlnch eliminanch metod na renln eliminovan psychofarmaka, pedevm tiaprid, amisulprid, sulpirid, risperidon, paliperidon, venlafaxin, lithium a dal. Rovn je vnovna pozornost vlivu hypoproteinemie, kter se rozvj u pacient s nefrotickm syndromem na farmakokinetiku a bezpenost terapie valprotem.

Authors

Publication Details

Journal
Psychiatrie pro praxi
Published
2025-07-04
DOI
https://doi.org/10.36290/psy.2025.020
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Altered pharmacokinetics of selected psychopharmaceuticals in patients with chronic kidney disease

Jan Miroslav Hartinger, M. Jelı́nková
1 links
Psychiatrie pro praxi
Pharmacogenetics and Drug Metabolism
article

Altered pharmacokinetics of selected psychopharmaceuticals in patients with chronic kidney disease

Jan Miroslav Hartinger, M. Jelı́nková
article en

Abstract

Psychiatrick onemocnn a delirantn stavy len psychofarmaky jsou astou komorbiditou u pacient s pokozenm ledvin. Akoliv je zait pedstava, e vtina psychofarmak je lipofiln povahy a renln se neeliminuj, tak pro celou adu bn podvanch liv to neplat a jejich dvkovn je nutn u pacient s chronickm onemocnnm ledvin (CKD), nebo akutnm pokozenm ledvin (AKI) upravit. Pedkldan lnek se vnuje vlivu zhorench ledvinovch funkc a extrakorporlnch eliminanch metod na renln eliminovan psychofarmaka, pedevm tiaprid, amisulprid, sulpirid, risperidon, paliperidon, venlafaxin, lithium a dal. Rovn je vnovna pozornost vlivu hypoproteinemie, kter se rozvj u pacient s nefrotickm syndromem na farmakokinetiku a bezpenost terapie valprotem.

Psychiatrie pro praxiVol. 26(2)
Good health and well-being
Openalex Percentile: Top 78%
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.